



FOR IMMEDIATE RELEASE

Board Changes

Sydney, Australia 28th November 2012 – The Board of NuSep (ASX:NSP) wishes to advise that Iain Sorrell, David Roffe and Ward Wescott will step down from the NuSep Board effective from the conclusion of the AGM on Friday 30 November 2012.

This will mean that Resolution 3 on the Notice of Meeting for the AGM, Re-election of Mr Iain Sorrell will be withdrawn. In addition, resolutions 2, 3 and 4 on the Notice of Meeting for the Extraordinary General Meeting scheduled for 30 November 2012, if required, will also be withdrawn.

The Board expects to announce the appointment of additional Board Members shortly.

“On behalf of the Company and Board I would like to thank Iain, David & Ward for their efforts since joining the Board and particularly over the last year”, said John Manusu, Chairman of NuSep holdings. “The Company has progressed significantly during the time that they have all been on the Board and it is now appropriate to bring on new skill sets which will help take us to a new level”, he added.

****ENDS****

For more information please contact:

Contact:
Swapna Keskar
Company Secretary
+61 2 8415 7300
keskar@company matters.com.au

About NuSep

NuSep (ASX: NSP) is a publicly listed life sciences company that sells products into the global BioSeparations market. NuSep recently acquired BioInquire which developed the ProteolQ software enabling NuSep to offer a total Proteomics solution from **Fraction to Function**. The company has offices in both Sydney Australia and Atlanta, USA.

With a 30 year heritage in biological separations, NuSep has forged a world class reputation for its innovative yet simple biological separation techniques including the world's first IVF sperm separation device. In short NuSep has redefined the BioSeparations market through innovation and simplification.

NuSep Holdings Ltd
324 Burns Bay Rd
Lane Cove NSW 2066





Postal Address
P.O. Box 823
Lane Cove NSW 1595

Contact Details
Telephone +61 2 8415 7300
Facsimile +61 2 8415 7399

Email info@nusep.com
Web www.nusep.com
ABN 33 120 047 556

NuSep's world renowned research team has developed an extensive portfolio of patented products. In all, NuSep currently manufactures, distributes and sells 55 products to customers in the USA, Europe, Asia and Australia.

NuSep Products:

-  **Gels** – NuSep manufactures and sells precast gels including the innovative nUView Gels, which can be visualised 2 minutes after use.
-  **Separation Instruments** – NuSep has developed two unique biological separation instruments. The ProteomeSep was released in 2009 and can separate biological samples into 8 fractions for use in the proteomic market. The SpermSep separates sperm for fertility treatments such as IVF.
-  **Proteomics Software** – NuSep offers the unique ProteoIQ software for the analysis of complex mass spec samples. This software is also designed to identify bio markers.
-  **Biological Products** – NuSep supplies research grade biological products manufactured using its unique separation technologies. These products include human IgG and Albumin.

For more information about NuSep please visit the company's website www.NuSep.com

About PrIME Biologics Pte Ltd

PrIME Biologics is a Singapore based biotech company that has developed a disposable therapeutic plasma manufacturing process based on NuSep's PrIME Technology. NuSep has a 90% shareholding in PrIME Biologics. PrIME Biologics process is based on the **P**reparative **I**solation by **M**embrane **E**lectrophoresis (PrIME) technology developed by NuSep. PrIME provides disposable modular processing that is 'electronically' driven membrane fractionation.

The PrIME process increases product yields to over 90% relative to the existing process 50% while increasing product safety. The PrIME has been shown to remove virus, bacteria, endotoxins and prions which cause 'Mad Cow Disease'. Further, PrIME Biologics process can produce multiple plasma products in hours compared to days, which is required by the current manufacturers.

The initial application for the PrIME process will be the *Currently Unprocessable Plasma* which represents approximately 50% of all the plasma collected in many Asian countries.